Physician profile
Susan Coe
NPI 1609033315
$5,617.31
in general payments reported to CMS, 2019-2025
36 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $187 · 2021: $536 · 2022: $853 · 2023: $819 · 2024: $1,077 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,585.17 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $577.91 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.60 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $432.93 | 2019-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $323.68 | 2019-2023 | Dificid |
| Pfizer INC. | $288.27 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $262.88 | 2022-2025 | Dupixent |
| Genzyme Corporation | $237.27 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $228.97 | 2020-2024 | Ocaliva |
| Gilead Sciences, INC. | $178.68 | 2023-2025 | |
| Madrigal Pharmaceuticals | $151.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $106.70 | 2024-2025 | Omvoh, Zepbound |
| Celgene Corporation | $85.82 | 2021-2023 | Zeposia |
| Mallinckrodt Hospital Products INC. | $62.41 | 2025 | Terlivaz |
| Ferring Pharmaceuticals INC. | $55.74 | 2019-2023 | Rebyota |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $50.50 | 2024 | Sucraid |
| Intra-Sana Laboratories | $43.49 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $40.07 | 2025 | Iqirvo |
| Organon LLC | $33.21 | 2024-2025 | Renflexis, Hadlima |
| Vivus LLC | $31.64 | 2021-2024 | Qsymia |
| Boston Scientific Corporation | $29.72 | 2021-2022 | |
| Amgen INC. | $28.07 | 2023 | Avsola, Amjevita |
| Daiichi Sankyo INC. | $22.82 | 2022 | |
| Biocompatibles, INC. | $22.78 | 2019 | |
| Ardelyx, INC. | $22.31 | 2025 | Ibsrela |
| Celltrion USA INC. | $21.60 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $20.02 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.40 | 2021 | |
| Alfasigma USA, INC. | $16.00 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.13 | 2020 | |
| Ucb, INC. | $13.79 | 2019 | |
| Evoke Pharma, INC. | $12.14 | 2022 | |
| Braintree Laboratories, INC. | $12.13 | 2019 | |
| Shionogi INC | $11.96 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.96 | 2025 | Voquezna |
| Endogastric Solutions, INC | $8.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.